|
|
|
18.05.26 - 22:03
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common stock and 13,793 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in April and May 2026 as a material inducement to their employment....
|
|
|
|
|
|
|
11.05.26 - 16:09
|
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten....
|
|
|
08.05.26 - 16:54
|
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters′ Option to Purchase Additional Shares for Gross Proceeds of $805 Million (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics....
|
|
|
|
|
07.05.26 - 05:03
|
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.05.26 - 22:18
|
Cytokinetics Announces Proposed Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics....
|
|
|
05.05.26 - 17:30
|
Cytokinetics-Aktie: NBC feiert Daten-Knall und lukrativen Teil-Exit (Sharedeals)
|
|
|
Ein Durchbruch bei seinem Herzmedikament treibt das Biotechunternehmen Cytokinetics an der Börse in die Höhe. Mitglieder des No Brainer Club waren frühzeitig an Bord und blicken einmal mehr auf einen dunkelgrünen Portfoliotitel. Cytokinetics gab heute positive Topline-Ergebnisse aus der Phase-3-Studie ACACIA-HCM für den Wirkstoff Aficamten bekannt. Die Studie bei Patienten mit nicht-obstruktiver hypertropher Kardiomyopathie (HCM) […]
The post Cytokinetics-Aktie: NBC feiert Daten-Knall und lukrativen Teil-Exit first appeared on sharedeals.de....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
